Copyright
©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Jul 26, 2019; 7(14): 1764-1774
Published online Jul 26, 2019. doi: 10.12998/wjcc.v7.i14.1764
Published online Jul 26, 2019. doi: 10.12998/wjcc.v7.i14.1764
New treatment modalities in Alzheimer's disease
Emel Koseoglu, Department of Neurology, Faculty of Medicine, Erciyes University, Kayseri 38039, Turkey
Author contributions: Koseoglu E designed and wrote this review.
Conflict-of-interest statement: The author declares no conflict of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Emel Koseoglu, MD, Professor, Department of Neurology, Faculty of Medicine, Erciyes University, Kayseri 38039, Turkey. emelk@erciyes.edu.tr
Telephone: +90-352-2076666/21755 Fax: +90-352-4374931
Received: March 21, 2019
Peer-review started: March 23, 2019
First decision: April 18, 2019
Revised: May 18, 2019
Accepted: June 10, 2019
Article in press: June 10, 2019
Published online: July 26, 2019
Processing time: 128 Days and 16.1 Hours
Peer-review started: March 23, 2019
First decision: April 18, 2019
Revised: May 18, 2019
Accepted: June 10, 2019
Article in press: June 10, 2019
Published online: July 26, 2019
Processing time: 128 Days and 16.1 Hours
Core Tip
Core tip: This review discusses various new treatment modalities in Alzheimer’s disease (AD) based on the classification of their mechanism of action. New anti-amyloid, anti-tau, and treatments targeting network dysfunction with particular attention to deep brain stimulation to modulate gamma oscillations in the brain are evaluated. Moreover exciting developments in stem cell therapy especially combined with tissue engineering techniques are presented. Lastly some other modalities including microglial function modulators, gut microbiome transplantation, modulation of vagus nerve and metabolic arrangements are mentioned. It seems that new treatments in AD will involve each of them individually or in combination.